Provided by Tiger Trade Technology Pte. Ltd.

OKYO Pharma Limited

1.45
0.0000
Volume:122.96K
Turnover:174.62K
Market Cap:76.09M
PE:-6.04
High:1.47
Open:1.40
Low:1.40
Close:1.45
52wk High:3.20
52wk Low:1.34
Shares:52.48M
Float Shares:28.04M
Volume Ratio:1.82
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2400
EPS(LYR):-0.2400
ROE:-263.78%
ROA:-43.09%
PB:6.17
PE(LYR):-6.04

Loading ...

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

GlobeNewswire
·
Sep 09

OKYO Pharma Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 08

Piper Sandler Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)

TIPRANKS
·
Aug 27

OKYO Pharma Files Form 3 for Chief Scientific Officer Rajkumar V. Patil

Reuters
·
Jul 30

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

GlobeNewswire
·
Jul 28

OKYO Pharma Joins BTIG Biotechnology Conference 2026

Reuters
·
Jul 27

OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
Jul 27

OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial

TIPRANKS
·
Jul 24

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

TIPRANKS
·
Jul 24

OKYO Pharma Director Brancaccio Raises Stake to 35,201 Shares After $1.48 Purchase

Reuters
·
Jul 24

Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share

TIPRANKS
·
Jul 23

OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial

TIPRANKS
·
Jul 22

OKYO Pharma CDO Jacob Lifts Stake to 112,420 Shares with 3,500-share Buy at $1.4

Reuters
·
Jul 22

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

GlobeNewswire
·
Jul 22

OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial

TIPRANKS
·
Jul 21

Okyo Pharma Says Chairman Gabriele Cerrone Boosts Stake to 20.5%

MT Newswires Live
·
Jul 21

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

GlobeNewswire
·
Jul 21

OKYO Pharma Chairman Raises Stake to 20.51% After Buying 25,000 Shares at $ 1.4

Reuters
·
Jul 21

OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial

TIPRANKS
·
Jul 20

OKYO Pharma Says Cash Position Funds Completion of Neptune Phase 3 Urcosimod Trial

Reuters
·
Jul 20